Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Also in this story
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.
- Moderna and Merck developed a new therapy.
- Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.
The entities involved
-
Moderna
American biotechnology company
-
Merck
public company in Indonesia
-
Georgetown Lombardi Comprehensive Cancer Center
cancer center of Georgetown University
Nothing else this week.
Related events
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- Australian researchers announced a global cancer vaccine breakthrough on August 20, 2026, which subsequently boosted Moderna's share price.
- Moderna and Merck conducted a study on mRNA vaccine while Rob Sand campaigned for Iowa governor, proposing plans to tackle cancer.